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Background: The genus Rothia are nonmotile, aerobic or facultative an-
aerobic, non–spore-forming Gram-positive cocci, which are considered
low-grade pathogens with relatively few known virulence determinants.
Methods: During our retrospective, single-center cohort study, microbio-
logical data were collected corresponding to the 12-year period (January 1,
200 to December 31, 2017), at the Institute of Clinical Microbiology, Uni-
versity of Szeged.
Results: A total of 37 individual Rothia isolates were identified (3.1 ± 1.9/
years; range, 0–6 isolates), 28 were Rothia dentocariosa, 9 were Rothia
mucilaginosa. The affected patients presented with a slight female domi-
nance (21 of 37; female/male ratio, 1:31); the median age of the affected
patients was 57 years (range, 1–86 years). In the majority of blood cultures
(n = 22), Rothia species were the only isolated microorganisms. All of the
tested strains were susceptible to benzylpenicillin, vancomycin, ciproflox-
acin, moxifloxacin, linezolid, and rifampicin.
Conclusions: Rothia species may readily be misidentified as staphylo-
cocci, streptococci, or corynebacteria, both the clinical microbiologists
and physicians should be aware of the possible etiological role of these mi-
croorganisms during their clinical practice, especially if the relevant risk
factors are present in these patients.
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T he genus Rothia (first designated by Georg and Brown in1967) is a member of the Micrococcaeae family, which in-
cludes other genera, such as Arthrobacter, Dermacoccus, Kocuria,
Kytococcus, Micrococcus (which includes the species M. luteus),
Nesterenkonia, and Pediococcus.1 Rothia species (currently
encompassing 8 distinct species; seeT1 Table 1.) have undergone
several taxonomical changes in the last 3 decades, for example,
R. dentocariosa (the type species of the genus)was previously known
as Nocardia salivae, Staphylococcus salivarius, M. mucilaginosus,
and Stomatococcus mucilaginosus.2–5 These microorganisms are
nonmotile, aerobic or facultative anaerobic, non–spore-forming
Gram-positive cocci, which are normal constituents of the flora
of the human skin, oral cavity, oropharynx, and upper respiratory
tract.6,7 Rothia spp. are considered low-grade pathogens with rel-
atively few knownvirulence determinants; therefore, these species
are rarely significant pathogens in the context of immunocompe-
tent individuals, they are mainly considered as contaminants in
relevant cultures.8 Until recently, the clinical role of Rothia species
was mainly associated with periodontitis, pericoronitis, and dental
caries, in association with other well-known periodontopatho-
gens (such as Aggregatibacter actinomycetemcomitans, Eikenella
corrodens, Prevotella intermedia, Porphyromonas gingivalis, Trep-
onema denticola, etc.)9; in fact,R. mucilaginosa and/orR. denticola
are found in the throat cultures around 30% of healthy individ-
uals.10 However, the increasing role of Rothia species as oppor-
tunistic pathogens has been noted by several publications,
corresponding with the significant rise in the number of immu-
nocompromised patients and invasive surgical interventions
worldwide.7,11,12 The first case of invasive infection (ie, endo-
carditis) caused by Rothia species (namely, R. dentocariosa)
was published in 1978.7 Although infective endocarditis is still
the most prevalent type of invasive infection,13 other clinical
syndromes associated with these pathogens, such as bacter-
emia,6,14 peritonitis,15 meningitis,16 pneumonia,17 biliary tract
infections,6 skin and soft tissue infections,18 necrotizing fascii-
tis,6 bone and joint infections,19 and endophtalmitis20 have also
been described.
Available literature is limited on the epidemiology of Rothia
species in invasive infections; therefore, the significance of the
isolation of Rothia spp. from blood cultures is a controversial
topic, especially in case of the polymicrobial infections or if only
a single set of blood cultures was available.7 To make matters
more complicated, patients having periodontal lesions or ones that
have undergone dental surgery may present with transient Rothia
bacteremia, which usually clears without medical intervention, if
the patient has no underlying conditions affecting the immune sys-
tem.21 Most cases of invasive Rothia infection (according to the
literature) showed a high mortality rate or sequelae (eg, abscess
or fistula formation, abdominal aneurisms, peritonitis, vertebral
osteomyelitis, cerebral hemorrhages), the relevance of this bacte-
rium in blood cultures should be carefully considered in light of
the patient'smedical history.6,22,23 To date, no epidemiological study
addressed the topic of invasive Rothia infections in Hungary, there-
fore, the aim of our study was to describe the prevalence and anti-
microbial susceptibility of Rothia isolates from bloodstream
infections and to evaluate the demographic characteristics of these
infections at our institution over a 12-year surveillance period.
MATERIALS AND METHODS
Study Design and Data Collection
During our retrospective, single-center cohort study, micro-
biological data were collected corresponding to the 12-year period
between January 1, 2006, and December 31, 2017, at the Institute
of Clinical Microbiology, University of Szeged. The Department
of Bacteriology in the Institute serves as the primary bacteriolog-
ical diagnostic laboratory of the tertiary-care teaching hospital
(Albert Szent-Györgyi Clinical Center; Szeged, Hungary) in the
region; this health care center is responsible for the primary- and
specialized care of an estimated population of over 400,000
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people.24,25 Data collection was carried out manually by an elec-
tronic search of the records in the laboratory information system
of the institute, regarding blood culture samples positive for
Rothia spp. The starting date of data collection has been set from
the year 2006, because the electronic laboratory information sys-
temwas operational since that year. During the study, only the first
isolation of the bacteria per patient was included in the analysis;
however, isolates with different antibiotic susceptibilities from
the same patient were considered as different individual isolates.26
Time-to-positivity data corresponding to the positive blood cul-
ture bottles was also collected.27 Polymicrobial bacteremia was
defined by the isolation of more than one organism in a single
blood culture.27
Anonymized patient datawere also collected on patients who
had at least 1 positive aerobic blood culture for Rothia spp., which
was limited to sex, age at sample submission, and indication for
the submission of the blood culture samples.28 The study was
deemed exempt from ethics review by the institutional review
board, and informed consent was not required because data ano-
nymity was maintained.
Sample Processing and Identification of
Rothia Isolates
The processing of blood culture samples arriving to the Insti-
tute of Clinical Microbiology was carried out according to current
national and international guidelines.27,29 Between 2006 and
2012, the BD Bactec (Becton Dickinson, Franklin Lakes, NJ)
blood culture detection system was used for the incubation of
blood culture bottles, whereas between 2013 and 2017, the
BacT/ALERT 3D (bioMérieux, Marcy-l'Étoile, France) detection
system was used. Blood culture bottles were incubated for 5 days
(21 days, if endocarditis was suspected) in both of the abovemen-
tioned detection systems.27,29 If the relevant pathogens presented
in significant colony count, the plates were passed on for
further processing.
Between 2006 and 2012, presumptive phenotypic (biochem-
ical reaction-based) methods, namely, the API Coryne V2.0 kit
(bioMérieux, Marcy-l'Étoile, France; critical enzymatic reactions
on the test strips were α-glucosidase and pyrazinamidase positiv-
ity and alkaline-phosphatase and β-glucosidase negativity), and
the VITEK 2 Compact ID (bioMérieux, Marcy-l'Étoile, France)
were used for bacterial identification. After 2013, the abovemen-
tioned methods were complemented with the use of matrix-
assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF MS). Bacterial cells from colonies on culture
plates were transferred to a stainless-steel target. After drying at
ambient temperature, the cells were covered with 1 μL matrix
(α-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5%
trifluoro-acetic acid) before measurements. Mass spectrometry
was performed by the microFlex MALDI Biotyper (Bruker
Daltonics, Bremen, Germany), the technical details of the mea-
surements were described previously.27 The MALDI Biotyper
RTC 3.1 software (Bruker Daltonics, Bremen, Germany) and
theMALDI Biotyper Library 3.1 were used for spectrum analysis.
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed using
the Kirby-Bauer disk diffusion method (Liofilchem, Abruzzo,
Italy) on Mueller-Hinton agar plates, supplemented with 5%
defibrinated horse blood and 20 mg/L β-NAD (MH-F). The in-
terpretation of the results was based on EUCAST breakpoints
for Corynebacterium spp.7 The following antibiotics were
tested: benzylpenicillin (indicative of susceptibility for all other
β-lactam antibiotics), ciprofloxacin, moxifloxacin, vancomycin,
erythromycin, clindamycin, tetracycline, linezolid, and rifampi-
cin.7,14 During data analysis, intermediate-susceptible results were
grouped with and reported as resistant. Streptococcus pneumoniae
ATCC 49619 (MH-F), Staphylococcus aureus ATCC 29213
(MH),Enterococcus faecalisATCC29212 (MH),Proteus mirabilis
ATCC35659 (MH),Escherichia coliATCC25922 (MH),Klebsiella
pneumoniae ATCC 700603 (MH), and Pseudomonas aeruginosa
ATCC 27853 (MH) were used as quality control strains.
Statistical Analysis
Descriptive statistical analysis (including means or medians
with ranges and percentages to characterize data) was performed
using Microsoft Excel 2013 (Redmond, WA, Microsoft Corp.).
Additional statistical analyses were performed with SPSS soft-
ware version 24.0 (IBM SPSS Statistics for Windows 24.0, IBM
Corp. Armonk, NY), using theχ2 test and 2-sample test. P values
less than 0.05 were considered statistically significant.
RESULTS
Demographic Characteristics, Isolation Frequency
During the 12-year study period, a total of 37 individual
Rothia isolates were identified (3.1 ± 1.9/year; range, 0–6 isolates;
highest in 2013 and 2014 [n = 6], lowest in 2007 and 2012 [n = 0])
from blood culture samples. The number of isolates in the first
part of the surveillance period (2006–2009) was 6, whereas in
the second (2010–2013) and third (2014–2017) part of the study
period were 17 and 14, respectively (P = 0.015). All (n = 37) iso-
lates were from blood culture samples originating from inpatient
departments. The affected patients presented with a slight female
dominance (21 of 37; female/male ratio, 1:31); the age distribu-
tion of patients was the following: 0–5 years, n = 2; 6–35 years,
n = 3; 36–59 years, n = 18; and 60 years or older, n = 13. Overall,
TABLE 1. Members of the Rothia Genus and Their Relevance in Human Infections1–20
Species Date of Taxonomic Description Site of First Isolation Relevance in Human Infections
R. aeria 2004 Patient with endocarditis + (0–5%)
R. aerolata 2016 Patient with endocarditis + (0–5%)
R. amarae 2002 Sludge of a water sewer Ø
R. dentocariosa 1967 Patient with dental plaques + (25–60%)
R. endophytica 2013 Roots of Dysophylla stellata (Lour.) Ø
R. mucilaginosa 1982 Patient with endocarditis + (10–50%)
R. nasimurium 2000 Nasal discharge of a mouse Ø
R. terrae 2008 Soil (in Taiwan) Ø
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the median age of the affected patients was 57 years (range, 1–
86 years); there was no significant difference among men and
women (P = 0.97).
Nineteen of the 37 isolates originated from the intensive care
units of different profiles (cardiology-hematology, surgery, and
traumatology), 9 of 37 from the Department of Internal Medicine,
7 of 37 from the Department of Surgery, and 2 of 37 from the
Department of Pediatrics. Indications for blood culture sample
submission, associated with Rothia spp. bacteremia included
cardiovascular illnesses (15 of 37), hematological malignancies
(10/37) and solid tumors (5/37), recent trauma (4/37) and pneu-
monia (3/37). No submission corresponding to dental procedures
was noted during the surveillance period. Time-to-positivity on
the corresponding blood cultures showed the following distribu-
tion: 0 to 24 hours in 3 cases, 25 to 48 hours in 6 cases, 49 to
72 hours in 11 cases, 73 to 96 hours in 6 cases, 97 to 120 hours
in 7 cases, and over 120 hours in 4 cases.
Species Distribution and Susceptibility of
Rothia Isolates
Out of the 37 isolates, 28 were R. dentocariosa, whereas the
remaining 9 were R. mucilaginosa. In the majority of blood cul-
tures (n = 22), Rothia species were the only isolated microorg-
anism, whereas in 15 samples, additional species were also
isolated: CoNS (S. epidermidis, S. haemolyticus, and S. hominis;
n = 10); Escherichia coli, 3; S. aureus, 1; and Pseudomonas
aeruginosa, 1.
All of the tested strains were susceptible to benzylpenicillin,
vancomycin, ciprofloxacin, moxifloxacin, linezolid, and rifampi-
cin (37/37), whereas 2 of 37 isolates were resistant to tetracy-
clines, whereas 14 of 37 and 16 of 37 isolates were resistant to
erythromycin and clindamycin, respectively. No temporal trends
or statistically significant differences in resistance were observed
during the various parts of the study period (P > 0.05).
DISCUSSION
Our study aims to report on the prevalence of Rothia species
in bacteremia infections at a tertiary-care hospital in Hungary in a
12-year study period (2006–2017). Based on the results of the
study in our settings, on average, 3 cases of Rothia may be ex-
pected per year, predominantly corresponding to patients older
than 50 years, presenting with an acute illness or some predispos-
ing factors or immunosuppression. Rothia species are considered
infrequent etiological agents, which mainly affect immunocom-
promised patients (therefore, they may be considered as opportu-
nistic pathogens); however, the reports of infections caused by
these bacteria in immunocompetent individuals showed a sharp
increase since the 2000s, probably due to the significant advance-
ments in the accuracy of diagnostic modalities in clinical microbi-
ology laboratories.7,30,31 This was highlighted in our study, where
much more strains of Rothia were found after 2010, which could
be related to the introduction of MALDI-TOFMS–based identifi-
cation in the laboratory. The list of known risk factors for immu-
nocompetent and immunocompromised individuals for invasive
Rothia infections is presented inT2 Table 2. Among invasive infec-
tions, endocarditis has been the most frequently reported; how-
ever, other organ systems (meningitis, pneumonia, peritonitis,
skin, and soft tissue infections) may also be affected, especially
if the presence of an underlying illness centers around a specific
organ (eg, lung cancer and Rothia pneumonitis; in these cases,
diagnosis was reached from cultures of the pleural fluid and
bronchoalveolar lavage).6–20
Several case reports or case series in a single institution have
been published in the literature7,12,32–35; however, comprehensive
epidemiological studies on Rothia bacteremia are lacking. In a
10-year study at the Mayo Clinic (in Rochester, MI) between
2002 and 2011, 67 adult patients had positive blood cultures for
Rothia (6.7/year), of which 37.3% presented with symptoms of
septicemia and 28.3% had neutropenia and/or some sort of hema-
tological malignancy.7 As a part of another study in the United
States, spanning over 8 years (2006–2014), 29 patients (3.6/year)
with a median age of 58 years were detected; in this study, the use
of fluoroquinolones and the presence of intravascular catheters
during bacteremiawas highlighted.32 Our results show similarities
in both the quantitative aspects (ie, the number of cases/year) and
qualitative aspects (characteristics of locally affected patients) of
the abovementioned 2 reports.
Phenotypically, colonies of Rothia species may look similar
to Corynebacterium spp. and coagulase-negative Staphylococcus
(CoNS) species; from a clinical standpoint, the differentiation
among these pathogens is important, as there aremajor differences
in their virulence, prognosis of infection, and therapy.1–7,36 An-
other important distinction is between Rothia spp. and the taxo-
nomically close Pediococcus spp., as the latter are intrinsically
resistant to vancomycin.37 Colonies are predominantly nonhemo-
lytic on blood agar plates, their consistency (sticky or mucoid col-
onies) varies among the different members of the genus.1–7,36 In
native wet-mount stains or Gram stains, these microorganisms
present as pair or groups of cocci; however, they may present as
cocco-bacilli or form filamentous branches as well. When it
comes to biochemical/metabolic activity, Rothia species are
oxidase-negative, catalase-variable, and predominantly positive
for glucose, fructose, maltose, and sucrose fermentation (but negative
for lactose, mannitol, and xylose, which is an important diagnostic
landmark), nitrate reduction, esculin, and gelatin hydrolysis.1–7,36
They are susceptible to bacitracin and are unable to grow on cul-
ture media containing 5% NaCl (cf. staphylococci). Although
the pathogenic role of Rothia species is infrequent (however, they
are common culture contaminants, similar to other members of
TABLE 2. Known Risk Factors for Invasive Rothia Infections in
Immunocompetent and Immunocompromised
Individuals1–20,30–35
Immunocompetent Immunocompromised
Intravenous drug abuse Severe neutropenia
Cardiac valve diseases Corticosteroid therapy
Presence of prosthetic devices
(eg, heart valves)*
Immunological therapy
(eg, TNF-α inhibitors)
Presence of IVCs or CVCs* Prior use of broad-spectrum
antibiotics (eg, fluoroquinolones)
Hematological malignancies
Solid tumors
HIV infection
Diabetes mellitus
Chronic liver disease
Long-term alcohol abuse
CAPD
Extensive surgical/dental procedures
Poor dental hygiene
Mucositis
* May be a risk factor in both patient groups.
CAPD, continuous ambulatory peritoneal dialysis; HIV, human immu-
nodeficiency virus; IVC, intravascular catheter; CVC, central venous
catheter.
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the Micrococcaceae), they are predominantly found in the data-
bases of commercial biochemical reaction-based identification
kits for Gram-positive organisms, allowing for reliable (genus-
level) identification.7 For optimal species-level differentiation
among Rothia spp., the use of molecular methods (eg, polymerase-
chain reaction, 16S rRNA sequencing) or MALDI-TOF MS is usu-
ally required. In laboratories without the adequate facilities, Rothia
species may be misidentified; therefore, their clinical relevance in hu-
man infections may also be underreported.38 As with to other genera
that were previously considered as rare pathogens, increase in the in-
terest toward Rothia spp. in the literature will presumably increase.26
For the empiric therapy of these infections, ceftriaxone,
imipenem/cilastatin or meropenem, vancomycin, or the newer
fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) are
used.7 Based on the reports available in the literature, most (>99%)
ofRothia isolates are susceptible to penicillinG andV, aminopenicillins
(ampicillin, amoxicillin), first- to third-generation cephalosp-
orins, carbapenems, and vancomycin; the susceptibility to
fluoroquinolones (ciprofloxacin and newer agents) is similarly
high, estimated to be around 90% to 95%.4,6,7,10–20,22,23,30–36
The ratio of tetracycline (due to mutations in the tet efflux
pumps), and macrolide-lincosamide-streptogramine resistance
(due to several possible mutations in the targets of the respec-
tive antibiotics) is reported to be higher, 0% to 30% and 15%
to 75%, respectively.4,6,7,10–20,22,23,30–35,38–40 For this reason,
the use of these agents is not recommended as first-line drugs,
β-lactam antibiotics represent safer and more efficacious alter-
natives.7 In case of tetracycline resistance, the use of doxycy-
cline, minocycline, and tigecycline may still be appropriate
(however, tigecycline is not suitable for bacteremia, as it reaches
low serum levels).41
The following limitations of the present study should be
highlighted: (i) the retrospective study design; (ii) identification
of bacterial isolates from clinical samples has changed once (in
2013) during the study period; (iii) anamnestic data, laboratory
findings (eg, neutropenia, fever) were unavailable, therefore, cor-
relation between the presence of bacteremia and symptoms could
not be established (or their possible roles as contaminants); (iv)
antibiotic resistance was characterized by the disk diffusion
method only, the underlying genetic mechanisms were not further
studied26; (v) as the amount of isolates studied in this report is lim-
ited, the main strength of the present study is providing a brief ep-
idemiological snapshot, together with a very detailed reviewof the
findings available in the literature.
CONCLUSIONS
To summarize our results, Rothia species are infrequently
isolated Gram-positive organisms, which are increasingly recog-
nized as emerging opportunistic pathogens in immunocom-
promised patients, and also in immunocompetent individuals,
proven by their increasing occurrence found in the literature. As
Rothia species may readily be misidentified as staphylococci,
streptococci, or corynebacteria, both the clinical microbiologists
and physicians should be aware of the possible etiological role
of these microorganisms during their clinical practice, especially
if the relevant risk factors are present in these patients. According
to our findings and results in the literature, β-lactam antibiotics
may be considered as safe and appropriate choices for therapy,
taking into account that the emergence of resistant mutants is
a possibility.
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